The novel ataxia telangiectasia–mutated Rad3-related (ATR) inhibitor, ceralasertib, showed some promise in combination with olaparib in pediatric patients with tumors with DNA repair deficiencies.
The combination of olaparib and the investigational ATR inhibitor ceralasertib induced antitumor responses in children and adolescents with DNA repair-deficient tumors, according to phase 1 results of the AcSé-ESMART trial.The data, presented at American Association for Cancer Research Annual Meeting, also showed ceralasertib (AZD6738, AstraZeneca) plus olaparib (Lynparza, AstraZeneca) — a
The combination of PARP and ATR inhibition with olaparib and ceralasertib was tolerable but showed limited efficacy in pediatric patients with advanced malignancies harboring DNA replication stress and DNA repair deficiencies, according to findings from arm N of the phase 1/2 AcSé-ESMART trial.